Axelar commences AXL1717 Phase I/II brain tumour study in US

January 20, 2013, from MedWorm: Brain Tumor

Swedish biotech company Axelar has announced the commencement of its AXL1717 investigator-sponsored Phase I/II study in patients with brain tumours in the US. (Source: Drug Development Technology)

MedWorm Sponsor Message: Have a look at The Cancer and Oncology Daily, the new cancer portal with all the latest cancer news and research powered by MedWorm, updated daily.

View Source